PCSK9 drugs

Verve posts clean PCSK9 editor profile, teeing up Lilly decision

One year after axing an asset, the biotech has shown its Lilly-partnered successor can achieve similar LDL-C reductions without raising any red flags.

Nick Paul Taylor Apr 14, 2025 7:00am

Graphic of someone in a boat navigating the rise and fall of different data riding data plots like a wave

Verve halts VERVE-101 enrollment, focuses on 2nd PCSK9 editor

Apr 2, 2024 7:00am

Beam offloads Verve rights to Lilly for up to $600M

Oct 31, 2023 6:00am

An artists depiction of a heart with a clogged artery

LIB's cholesterol-busting drug hits goal in 2nd phase 3 trial

Aug 29, 2023 6:30am

start line beginning road path starting point journey

Merck bets big on oral PCSK9 inhibitor with phase 3 program

Aug 25, 2023 8:35am

Cholesterol-focused Esperion loses appetite for Serometrix pact

Aug 1, 2023 10:46am